PPD to acquire evidence-based solutions provider, Evidera

By Melissa Fassbender

- Last updated on GMT

There is a $6.8bn post-approval outsourcing market for CROs. (Image: iStock/HASLOO)
There is a $6.8bn post-approval outsourcing market for CROs. (Image: iStock/HASLOO)

Related tags Ppd

Pharmaceutical Product Development (PPD) is set to acquire evidence-based solutions provider Evidera, as the need for real-world data continues to grow.

David Simmons, PPDChairman and CEO, told us Evidera’s real-world research​ services will further strengthen PPD’s peri- and post-approval capabilities, “positioning PPD to fully partner with biopharmaceutical customers across the development continuum in evidence generation and analysis for innovative medicines​.”

Additionally, Simmons explained, “PPD’s global scale and partnerships with multiple biopharma clients will provide Evidera a strategic partner to fuel its long-term growth and synergistic opportunities​.”

Now more than ever, the industry must demonstrate value and effectiveness in real-world settings, as it facing increasing scrutiny. “This is becoming increasingly critical to justify access to, and payment for, products,​” Jon Williams, President and CEO, Evidera, told Outsourcing-Pharma.com.

It’s critical that evidence-based value demonstration start early and be well-integrated into the clinical development process​,” he added, as payers, health authorities, and providers are now demanding this as a condition for market access.

No therapeutic area is immune any longer from these requirements​,” said Williams.

However, according to Williams, not all organizations are able to partner with biopharma companies to help them do this well. “Today that changes​,” he said.

By marrying a best-in-class CRO with a best-in-class real-world research and market access company, PPD and Evidera can provide the evidence-based value demonstration that biopharma companies need. We believe this will be transformative​,” explained Williams.

Outpacing R&D

Recently, the industry has recognized a need to generate stronger evidence for how products perform outside the setting of a clinical trial– “in other words, in a real-world setting​,” said Williams.

Real-world evidence is needed to substantiate a product’s effectiveness and demonstrate its value to payers and health authorities to help optimize market access​,” he added – and the need for real-world evidence is increasing.

According to a Jefferies forecast, there is a $6.8bn post-approval outsourcing market for CROs.

Investment growth in this area is outpacing overall R&D spend​,” explained Simmons. “This is an area where Evidera will significantly expand and build on PPD’s existing capability to deliver the evidence required by regulators, payers and health technology assessment agencies​.”

The transaction is expected to close in the third quarter. In what it calls “a strategic differentiator​” to meet the needs of its clients, PPD does not plan to fully integrate Evidera into PPD.

Evidera will operate as a separate business unit, serving as the late-stage business unit of PPD with the full ability to tap into the comprehensive capabilities of PPD as a global CRO​,” said Simmons. “We believe this unique approach will support Evidera in continuing to maintain its industry-leading reputation​.”

Related news

Show more

Related products

show more

Saama accelerates data review processes

Saama accelerates data review processes

Content provided by Saama | 25-Mar-2024 | Infographic

In this new infographic, learn how Saama accelerates data review processes. Only Saama has AI/ML models trained for life sciences on over 300 million data...

More Data, More Insights, More Progress

More Data, More Insights, More Progress

Content provided by Saama | 04-Mar-2024 | Case Study

The sponsor’s clinical development team needed a flexible solution to quickly visualize patient and site data in a single location

Using Define-XML to build more efficient studies

Using Define-XML to build more efficient studies

Content provided by Formedix | 14-Nov-2023 | White Paper

It is commonly thought that Define-XML is simply a dataset descriptor: a way to document what datasets look like, including the names and labels of datasets...

Overcoming rapid growth challenges with process liquid preparation

Overcoming rapid growth challenges with process liquid preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 01-Nov-2023 | Case Study

A growing contract development manufacturing organization (CDMO) was challenged with the need to quickly expand their process liquid and buffer preparation...

Related suppliers

Follow us


View more